(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 14.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 6.63%.
Adaptive Biotechnologies's revenue in 2023 is $179,690,000.On average, 5 Wall Street analysts forecast ADPT's revenue for 2023 to be $25,525,462,820, with the lowest ADPT revenue forecast at $24,640,322,220, and the highest ADPT revenue forecast at $26,855,345,311. On average, 5 Wall Street analysts forecast ADPT's revenue for 2024 to be $33,358,682,058, with the lowest ADPT revenue forecast at $29,678,413,955, and the highest ADPT revenue forecast at $36,813,973,306.
In 2025, ADPT is forecast to generate $42,897,469,076 in revenue, with the lowest revenue forecast at $41,014,120,358 and the highest revenue forecast at $46,233,033,259.